June 13, 2022 -- A joint marketing agreement between Gencove and Element Biosciences is meant to further reduce the cost and complexity of obtaining genomic information.
Gencove offers low-pass whole-genome sequencing and analysis software, while Element Biosciences is the developer of the Element Aviti System, a new and disruptive DNA sequencing platform. The companies contend that by combining the performance and flexibility of the Aviti System with Gencove's software platform will democratize access to genomic information.
"Gencove and Element share a vision to make cost-effective, high-throughput genome-wide information universally available," said Gencove CEO Joseph Pickrell, PhD, in a statement. "This agreement moves the industry closer to ubiquitous sequencing to help solve our civilization's most pressing biological challenges."